5-Amino-1MQ: Metabolic Modulation Through NNMT Inhibition

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is more active in the fat tissue of obese animals and people. In diet-induced obese mice, blocking NNMT with 5-Amino-1MQ reduced body weight and fat mass. As of this writing, it has not been tested in completed human trials, it is not FDA-approved, and its long-term safety in people is unknown.

That combination, an elegant mechanism plus only animal data, is common in metabolic research. It is worth understanding both why scientists find NNMT interesting and why that interest has not yet translated into a treatment I can recommend with confidence.

What is 5-Amino-1MQ?

Despite frequently appearing on peptide menus, 5-Amino-1MQ is not a peptide. It is 5-amino-1-methylquinolinium, a small, membrane-permeable molecule designed in the laboratory to block NNMT selectively. Because it is small, it is typically discussed as an oral compound, which partly explains its popularity online.

How NNMT inhibition works

NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine (SAM), the body's main methyl donor, onto nicotinamide, a form of vitamin B3. The products are 1-methylnicotinamide and S-adenosylhomocysteine.

Why does that matter for metabolism?

• NAD+ availability. Nicotinamide is a building block for NAD+, a coenzyme central to cellular energy metabolism. When NNMT methylates nicotinamide, less of it is recycled into NAD+.
• Methyl donor balance. NNMT consumes SAM. Changing NNMT activity can shift the methylation cycle, which links to homocysteine metabolism.
• Fat-cell energy use. In adipose tissue, reducing NNMT activity appears to increase energy expenditure in fat cells, at least in animal models.

The key animal research

In 2014, researchers reported in Nature that NNMT expression is increased in the fat tissue of obese mice and that knocking down NNMT in fat and liver protected mice against diet-induced obesity, with increased energy expenditure. That work made NNMT a plausible metabolic target.

Later, a team developed selective small-molecule NNMT inhibitors, including 5-Amino-1MQ. In diet-induced obese mice, treatment reduced body weight, white fat mass and adipocyte size, and lowered cholesterol, without a reported reduction in food intake. A small number of follow-up animal studies have also explored NNMT inhibition in aged muscle.

What we do not know

The gap between mouse data and human medicine is wide, and in metabolism it is often where promising compounds fail. Important open questions include:

• Efficacy in humans. Mice on high-fat diets are an imperfect model of human obesity. Effects seen in mice may be smaller, different, or absent in people.
• Dose and exposure. Without human pharmacokinetic studies, nobody knows what dose achieves meaningful NNMT inhibition safely.
• Off-target effects. NNMT is active in the liver as well as fat. What long-term systemic inhibition does to liver metabolism, methylation and other pathways is not established.
• Methylation and homocysteine. Because NNMT sits within the methylation cycle, changes in homocysteine are a theoretical concern worth monitoring.
• Product quality. Compounds sold online for "research use" have no reliable assurance of identity, purity or dose.

FDA status of 5-Amino-1MQ

5-Amino-1MQ is not FDA-approved for any indication. It is also not an established dietary ingredient with a human safety record. Its regulatory pathway for compounding is uncertain; as of this writing, check current FDA guidance rather than relying on marketing claims. Investigational status does not mean "illegal and dangerous" in every case, but it does mean the burden of proof has not been met.

How 5-Amino-1MQ compares with proven options

When patients bring up 5-Amino-1MQ, the underlying goal is usually fat loss, especially abdominal fat, while preserving muscle. For that goal there are options with far stronger human evidence:

1. Nutrition and resistance training. Still the foundation, especially for preserving lean mass during weight loss.
2. Sleep and stress. Poor sleep worsens insulin resistance and appetite regulation.
3. FDA-approved medications. GLP-1 based therapies such as semaglutide and tirzepatide have large randomized trials behind them. I discuss them in GLP-1 medications and longevity.
4. Treating what is driving the weight. Thyroid disease, medications that promote weight gain, sleep apnea and insulin resistance should be identified first.

Many people interested in NNMT are really interested in NAD+ biology. That topic has its own evidence base and limits, reviewed in NAD therapy: injections vs capsules vs IV and in the NMN entry in our peptide library.

What I check before any metabolic discussion

In my practice, I start with labs, because metabolic problems are measurable. A typical starting point includes HbA1c, fasting glucose and insulin, a lipid panel, liver enzymes, thyroid function, and, where methylation is relevant, homocysteine and B12. Body composition and waist circumference add context. The broader framework is described in metabolic health markers every adult should track.

If an investigational compound is ever discussed, it is only after that evaluation, with a clear explanation that the evidence is preclinical, a defined monitoring plan, and individualized decisions about whether it is appropriate at all. Dosing of investigational compounds is not something I publish or recommend outside of a full evaluation.

The bottom line on 5-Amino-1MQ

NNMT is a legitimately interesting metabolic target, and 5-Amino-1MQ is a reasonable research tool for studying it. But "promising in mice" is not the same as "effective in people." Until human trials report, it belongs in the category of unknowns.

At Laeeq M.D., Dr. Laeeq focuses first on proven metabolic care, and discusses investigational options honestly, including when the right answer is to wait. You can see our summary in the peptide library.

Sources

• Kraus D, et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature, 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4107212
• Neelakantan H, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology, 2018. https://researchexperts.utmb.edu/en/publications/selective-and-membrane-permeable-small-molecule-inhibitors-of-nic/

Book a Consultation

If you are working on body composition or metabolic health and want an honest look at your options, book a consultation with Dr. Laeeq. The 60-minute visit is available virtually or in person in Reston, VA, and starts with your labs and history.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.